What is the main purpose of the agreement between Gilead and Tibotec?

The primary purpose of the agreement is to combine Gilead's Truvada with Tibotec's investigational drug TMC278 into a single, once-daily oral fixed-dose combination (FDC) product for the treatment of adults. Gilead will lead the development and commercialization of this FDC in specified territories.

What are Gilead's financial obligations under this agreement?

Gilead is obligated to pay up to €71,450,000 of Tibotec's development costs for TMC278. Additionally, Gilead will purchase TMC278 for use in the FDC, with the cost approximating the market price less a discount of up to 30%.

Which territories are covered by this license agreement?

The license granted to Gilead is for the development and commercialization of the fixed-dose combination product on a worldwide basis, excluding low-income countries and Japan.

What are the conditions under which either party can terminate the agreement?

The agreement can be terminated under several conditions, including market withdrawal of the product, material breach, failure of the TMC278 clinical program, lack of timely approval, or unwillingness to conduct required additional clinical studies. Termination rights are also tied to the expiration of relevant patents for Truvada and TMC278.

GILD 8-K: Material Agreements

Summary

Gilead Sciences, Inc. (GILD) announced a significant strategic partnership with Tibotec Pharmaceuticals, a subsidiary of Johnson & Johnson, on July 16, 2009. This agreement centers on the development and commercialization of a novel fixed-dose combination (FDC) product. The FDC will combine Gilead's established Truvada (emtricitabine/tenofovir disoproxil fumarate) with Tibotec's investigational drug TMC278 (rilpivirine hydrochloride), which was in Phase III trials at the time. This collaboration aims to create a once-daily oral treatment for adults, excluding low-income countries and Japan, representing a substantial expansion of Gilead's HIV treatment portfolio. The agreement outlines specific responsibilities and financial commitments. Gilead will lead the development, formulation, registration, and commercialization of the FDC in its licensed territories, while Tibotec will focus on the development and approval of TMC278. Gilead will also cover a portion of Tibotec's development costs for TMC278 and will benefit from a discount on the cost of TMC278 incorporated into the FDC. This partnership signals Gilead's commitment to advancing HIV therapy through combination products and leveraging its existing successful therapies.

Key Highlights

1Gilead Sciences entered into a material definitive agreement with Tibotec Pharmaceuticals (Johnson & Johnson subsidiary) on July 16, 2009.
2The agreement is for the development and commercialization of a fixed-dose combination (FDC) product.
3The FDC will combine Gilead's Truvada with Tibotec's investigational TMC278 (rilpivirine hydrochloride).
4Gilead gains an exclusive license to develop and commercialize the FDC in adults, once-daily oral dosage, worldwide excluding low-income countries and Japan.
5Gilead will contribute up to €71,450,000 towards Tibotec's development costs for TMC278.
6Gilead will manufacture and lead registration, distribution, and commercialization of the FDC.
7The agreement includes detailed provisions for termination, patent expiration, and pricing of the combination product.

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Jul 16, 2009)

Summary

Key Highlights

Frequently Asked Questions